Voyager Therapeutics Inc (VYGR) Receives Average Rating of “Buy” from Brokerages
Voyager Therapeutics Inc (NASDAQ:VYGR) has been given a consensus recommendation of “Buy” by the fifteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $26.33.
Several research firms recently commented on VYGR. Stifel Nicolaus restated a “buy” rating and issued a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Cowen restated a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, October 31st. ValuEngine lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Piper Jaffray Companies reiterated an “overweight” rating and set a $28.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, November 28th. Finally, Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th.
Voyager Therapeutics (VYGR) traded down $0.74 during midday trading on Friday, reaching $13.88. 335,000 shares of the company traded hands, compared to its average volume of 251,261. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of Voyager Therapeutics by 20.9% during the second quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock valued at $477,000 after purchasing an additional 9,207 shares during the period. Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after buying an additional 13,194 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Voyager Therapeutics by 9.3% in the second quarter. Wells Fargo & Company MN now owns 91,384 shares of the company’s stock worth $819,000 after buying an additional 7,807 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Voyager Therapeutics in the third quarter worth $5,155,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of Voyager Therapeutics in the third quarter worth $1,122,000. Institutional investors own 35.97% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Voyager Therapeutics Inc (VYGR) Receives Average Rating of “Buy” from Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/15/voyager-therapeutics-inc-vygr-receives-average-rating-of-buy-from-brokerages.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.